

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously Presented) A method for treating hypercalcemic crisis associated with malignant tumor comprising  
administering to a patient a humanized anti-PTHrP antibody capable of inhibiting the binding between PTHrP and a receptor thereof;  
allowing the antibody to inhibit the binding of PTHrP to a receptor thereof;  
decreasing a blood calcium level by at least 1 mg/dL within 24 hours to effectively treat the patient; and  
maintaining the at least 1 mg/dL decrease in blood calcium level over at least 24 hours, wherein said blood calcium level decreases to below 15 mg/dL.
- 2-3. (Canceled)
4. (Previously Presented) The method according to claim 1, wherein the humanized anti-PTHrP antibody is an antibody fragment capable of inhibiting the binding between PTHrP and a receptor thereof.
5. (Canceled)
6. (Previously Presented) The method according to claim 1, wherein the humanized antibody is humanized antibody deposited under Accession No. FERM BP-5631.

7-8. (Canceled)

9. (Previously Presented) The method according to claim 1, wherein the hypercalcemic crisis is associated with at least one of coma or cardiac arrest.

10. (Previously Presented) The method according to claim 1 or 4, wherein the antibody is bound to a carrier.

11. (Previously Presented) The method according to claim 10, wherein the carrier is PEG.

12. (Previously Presented) The method according to claim 4, wherein the fragment is chosen from at least one of Fab, scFv, F(ab')<sub>2</sub>, and Fv.

13. (Previously Presented) A method for treating hypercalcemic crisis associated with malignant tumor comprising  
administering to a patient a humanized anti-PTHrP antibody inhibiting the binding between PTHrP and a receptor thereof;  
allowing the antibody to inhibit the binding of PTHrP and a receptor thereof;  
decreasing a blood calcium level to below 15.0 mg/dl to effectively treat the patient.

14. (Previously Presented) The method according to claim 13, wherein the patient is administered at least one fragment of the humanized anti-PTHrP antibody.

15. (Previously Presented) The method according to claim 14, wherein the fragment is chosen from at least one of Fab, scFv, F(ab')<sub>2</sub>, and Fv.

16. (Previously Presented) The method according to claim 13, wherein the humanized antibody is humanized antibody deposited under Accession No. FERM BP-5631.

17-18. (Canceled)

19. (Previously Presented) The method according to claim 13, wherein the hypercalcemic crisis is associated with at least one of coma or cardiac arrest.

20. (Previously Presented) The method according to claim 13 or 14, wherein the antibody is bound to a carrier.

21. (Previously Presented) The method according to claim 20, wherein the carrier is PEG.

22-32. (Canceled)

33. (Previously Presented) The method according to claim 1, wherein the blood calcium level is decreased by at least 2 mg/dL.

34. (New) A method for treating hypercalcemic crisis associated with malignant tumor, comprising

- administering to a patient a humanized anti-PHTrP antibody inhibiting the binding between PTHrP and a receptor thereof;
- allowing the antibody to inhibit the binding of PTHrP and a receptor thereof;
- decreasing a blood calcium level to effectively treat the patient.

35. (New) The method according to claim 34, wherein the hypercalcemic crisis is defined as a blood calcium level that does not normalize after 24 hours of treatment and remain normal over at least 24 hours with one of the therapeutic agents chosen from biphosphonate, calcitonin, a steroid, phosphate buffer, physiological saline, and furosemide.

36. (New) The method according to claim 35, wherein the normal blood calcium level is less than 12 mg/dl.

37. (New) The method according to claim 34, wherein the patient is administered at least one fragment of the humanized anti-PTHrP antibody.

38. (New) The method according to claim 37, wherein the fragment is chosen from at least one of Fab, scFv, F(ab')<sub>2</sub>, and Fv.

39. (New) The method according to claim 34, wherein the humanized antibody is humanized antibody deposited under Accession No. FERM BP-5631.

40. (New) The method according to claim 34, wherein the hypercalcemic crisis is associated with at least one of coma or cardiac arrest.

41. (New) The method according to claim 34 or 37, wherein the antibody is bound to a carrier.

42. (New) The method according to claim 41, wherein the carrier is PEG.